| Primary |
| Prophylaxis Of Nausea And Vomiting |
48.9% |
| Breast Cancer |
25.1% |
| Nausea |
4.0% |
| Lung Neoplasm Malignant |
3.6% |
| Chemotherapy |
3.1% |
| Prophylaxis |
3.1% |
| Neoplasm Malignant |
1.8% |
| Colon Cancer |
1.3% |
| Non-small Cell Lung Cancer |
1.3% |
| Pharyngeal Cancer |
1.3% |
| Antiemetic Supportive Care |
0.9% |
| Breast Cancer Recurrent |
0.9% |
| Dizziness |
0.9% |
| Premedication |
0.9% |
| Anal Fissure |
0.4% |
| Anxiety |
0.4% |
| Constipation |
0.4% |
| Fluid Replacement |
0.4% |
| Gastric Disorder |
0.4% |
| Gastritis Prophylaxis |
0.4% |
|
| Injection Site Phlebitis |
18.4% |
| Injection Site Pain |
10.2% |
| Injection Site Induration |
9.2% |
| Injection Site Vasculitis |
8.2% |
| Infusion Site Pain |
7.1% |
| Anaphylactic Shock |
4.1% |
| Flushing |
4.1% |
| Injection Site Swelling |
4.1% |
| Rash |
4.1% |
| Vomiting |
4.1% |
| Anaphylactic Reaction |
3.1% |
| Blood Pressure Increased |
3.1% |
| Burning Sensation |
3.1% |
| Dyspnoea |
3.1% |
| Nausea |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
| Bronchospasm |
2.0% |
| Convulsion |
2.0% |
| Erythema |
2.0% |
| Haemolytic Uraemic Syndrome |
2.0% |
|
| Secondary |
| Prophylaxis Of Nausea And Vomiting |
40.3% |
| Breast Cancer |
26.8% |
| Colon Cancer |
12.1% |
| Nausea |
6.0% |
| Non-small Cell Lung Cancer |
2.7% |
| Pharyngeal Cancer |
2.0% |
| Urticaria |
2.0% |
| Anal Fissure |
1.3% |
| Chemotherapy |
1.3% |
| Gastric Disorder |
1.3% |
| Gastritis Prophylaxis |
1.3% |
| Tumour Pain |
1.3% |
| Neoplasm Malignant |
0.7% |
| Vomiting |
0.7% |
|
| Injection Site Phlebitis |
22.6% |
| Injection Site Vasculitis |
11.3% |
| Vomiting |
11.3% |
| White Blood Cell Count Decreased |
9.4% |
| Dyspnoea |
5.7% |
| Gastric Ulcer Haemorrhage |
5.7% |
| Burning Sensation |
3.8% |
| Drug Level Increased |
3.8% |
| Injection Site Pain |
3.8% |
| Thrombophlebitis |
3.8% |
| Anaphylactic Reaction |
1.9% |
| Blood Pressure Increased |
1.9% |
| Flushing |
1.9% |
| Hypotension |
1.9% |
| Injection Site Erythema |
1.9% |
| Injection Site Reaction |
1.9% |
| Large Intestine Perforation |
1.9% |
| Muscle Twitching |
1.9% |
| Nausea |
1.9% |
| Rash |
1.9% |
|
| Concomitant |
| Premedication |
22.2% |
| Pain |
11.1% |
| Bladder Cancer |
7.9% |
| Breast Cancer |
6.3% |
| Product Used For Unknown Indication |
6.3% |
| Head And Neck Cancer |
4.8% |
| Oral Candidiasis |
4.8% |
| Constipation |
3.2% |
| Dehydration |
3.2% |
| Gallbladder Cancer Metastatic |
3.2% |
| Hypertension |
3.2% |
| Insomnia |
3.2% |
| Nausea |
3.2% |
| Neutropenia |
3.2% |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive Stage I |
3.2% |
| Prophylaxis |
3.2% |
| Supplementation Therapy |
3.2% |
| Antiemetic Supportive Care |
1.6% |
| Anxiety |
1.6% |
| Cataplexy |
1.6% |
|
| Arrhythmia |
15.4% |
| Intestinal Perforation |
15.4% |
| Blood Pressure Increased |
7.7% |
| Colon Cancer |
7.7% |
| Flank Pain |
7.7% |
| Renal Failure Chronic |
7.7% |
| Respiratory Arrest |
7.7% |
| Sudden Death |
7.7% |
| Transient Ischaemic Attack |
7.7% |
| Upper-airway Cough Syndrome |
7.7% |
| Urinary Retention |
7.7% |
|
